Hemophilia B

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

Movement Disorders
Movement Disorders
FDA Approves First Drug to Treat Tardive Dyskinesia
04/12/2017
The US Food and Drug Administration has approved a new capsule for the treatment of the neurological disorder tardive dyskinesia.
04/12/2017
Hepatitis C
Hepatitis C
FDA Approves New Options for Pediatric Patients With Hepatitis C
04/07/2017
The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.
04/07/2017
Hepatitis C
Hepatitis C
FDA Approves New Options for Pediatric Patients With Hepatitis C
04/07/2017
The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.
04/07/2017
Hepatitis C
Hepatitis C
FDA Approves New Options for Pediatric Patients With Hepatitis C
04/07/2017
The FDA has approved 2 new treatment options for children aged 12 to 17 with hepatitis C infection.
04/07/2017
Movement Disorders
Movement Disorders
FDA Approves Austedo for Treatment of Huntington Disease-Associated Chorea
04/04/2017
The US Food and Drug Administration has approved Austedo (deutetrabenazine) tablets for the treatment of chorea in patients with Huntington disease.
04/04/2017
FDA
FDA
FDA Expands Indication for Metastatic Breast Cancer Treatment
04/03/2017
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
04/03/2017
FDA
FDA
FDA Expands Indication for Metastatic Breast Cancer Treatment
04/03/2017
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
04/03/2017
FDA
FDA
FDA Expands Indication for Metastatic Breast Cancer Treatment
04/03/2017
The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
04/03/2017
Lung cancer
Lung cancer
FDA Approves Tagrisso for Non-Small Cell Lung Cancer
03/31/2017
The FDA approved osimertinib for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
03/31/2017
Lung cancer
Lung cancer
FDA Approves Tagrisso for Non-Small Cell Lung Cancer
03/31/2017
The FDA approved osimertinib for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
03/31/2017